Alpha-1 Antitrypsin Deficiency Clinical Trial
— rhAAT-FcOfficial title:
An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD)
Verified date | September 2022 |
Source | Inhibrx, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label, 2-part, dose-escalating, Phase 1 study of INBRX-101 (rhAAT-Fc). Part 1 will consist of single ascending dose (SAD) administration of INBRX-101 and Part 2 will consist of multiple ascending dose (MAD) administrations of INBRX-101. The planned dosing schedule is IV every 3 to 4 weeks.
Status | Completed |
Enrollment | 31 |
Est. completion date | August 18, 2022 |
Est. primary completion date | August 18, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Documented alpha-1 antitrypsin (AAT) serum concentration <11 µM. - Diagnosis of alpha-1 antitrypsin deficiency (AATD) with any allelic combination with exception of the null/null genotype. - For subjects in Part 2 80 and 120 mg/kg cohorts ONLY: post-bronchodilator FEV1 of at least 40% of predicted normal value. - For subjects in Part 2 80 and 120 mg/kg cohorts ONLY: subjects eligible for bronchoscopy per judgment of investigator. - Nonsmoker for at least 6 months prior to study and must remain nonsmoking for the entire study duration. - Adequate hepatic and renal function as defined per protocol. - Willing to undergo current augmentation therapy washout (if applicable) and refrain from initiating augmentation therapy, other investigational drug trials for AATD, therapy with IV immunoglobulins or monoclonal antibodies during the entire study, including follow-up. Exclusion Criteria: - Known or suspected allergy to components of INBRX-101 (AAT or human IgG) or pdAAT. - Participation in any investigational drug trial within 30 days prior to this trial, or subjects receiving IV immunoglobulins or monoclonal antibodies within 30 days prior to this trial. - History of and/or on the waiting list for lung or liver transplant, lobectomy, or lung volume reduction surgery. - Acute respiratory tract infection or COPD exacerbation that required antibiotic treatment and/or increase in systemic steroid dosage within the 4 weeks prior to screening. Subjects are permitted to continue to receive steroids if the investigator judges the subject to have a history of stable dosing. - Subjects with ongoing or history of unstable cor pulmonale. - Infection with hepatitis A, B, or C or human immunodeficiency virus (HIV). - Active autoimmune disease or documented history of autoimmune disease that 1) required systemic steroids or immune-suppressive medications and 2) tested positive for auto-antibodies. Exception: Endocrinopathies managed with hormone replacement therapy (HRT). - Current substance and/or alcohol abuse with protocol defined exceptions. - Current narcotics abuse with protocol defined exceptions. |
Country | Name | City | State |
---|---|---|---|
New Zealand | The New Zealand Respiratory and Sleep Institute | Auckland | |
New Zealand | Christchurch Clinical Studies Trust Ltd | Christchurch | |
New Zealand | Waikato Respiratory and Gastro Research Unit | Hamilton | |
United Kingdom | University Hospital Birmingham NHS Foundation Trust | Birmingham | West Midlands |
United Kingdom | University of Cambridge | Cambridge | East Of England |
United States | University of Florida College of Medicine | Gainesville | Florida |
United States | Hannibal Clinic | Hannibal | Missouri |
United States | Indiana University | Indianapolis | Indiana |
United States | University of Miami | Miami | Florida |
United States | UC Davis School of Medicine | Sacramento | California |
Lead Sponsor | Collaborator |
---|---|
Inhibrx, Inc. |
United States, New Zealand, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of adverse events of INBRX-101 | Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03. | Up to 7 months | |
Primary | Severity of adverse events of INBRX-101 | Severity of adverse events will be assessed and assigned by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03. | Up to 7 months | |
Secondary | Area under the serum concentration time curve (AUC) of INBRX-101 | Area under the serum concentration time curve (AUC) of INBRX-101 will be determined. | Up to 7 months | |
Secondary | Maximum observed serum concentration (Cmax) of INBRX-101 | Maximum observed serum concentration (Cmax) of INBRX-101 will be determined. | Up to 7 months | |
Secondary | Trough observed serum concentration (Ctrough) of INBRX-101 | Trough observed serum concentration (Cmax) of INBRX-101 will be determined. | Up to 7 months | |
Secondary | Time to Cmax (Tmax) of INBRX-101 | Time to Cmax (Tmax) of INBRX-101 will be determined. | Up to 7 months | |
Secondary | Half-life (T1/2) of INBRX-101 | Half-life of INBRX-101 will be determined. | Up to 7 months | |
Secondary | Immunogenicity of INBRX-101 | Frequency and consequences of anti-drug antibodies (ADA) against INBRX-101 will be determined. | Up to 7 months | |
Secondary | Distribution of INBRX-101 in Bronchoalveolar Lavage Fluid (BALF) | The concentration of INBRX-101 in bronchoalveolar lavage fluid (BALF) be determined. | Up to 7 months | |
Secondary | Functional concentration of INBRX-101 in serum and BALF | The functional concentration of INBRX-101 in serum and BALF will be determined. | Up to 7 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02547532 -
Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency
|
||
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT00005292 -
Alpha1-antitrypsin Deficiency Registry
|
N/A | |
Withdrawn |
NCT02900183 -
Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels
|
Phase 2 | |
Terminated |
NCT02502201 -
Environment Effect on Six-Minute Walk Test Performance
|
N/A | |
Completed |
NCT01810458 -
Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
|
||
Active, not recruiting |
NCT04262284 -
Respreeza® Self-administration and Learning Program (AmAREtTI Study)
|
||
Recruiting |
NCT06186492 -
A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)
|
Phase 1 | |
Recruiting |
NCT06405633 -
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
|
Phase 1/Phase 2 | |
Completed |
NCT01054339 -
Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency
|
Phase 2 | |
Completed |
NCT03008915 -
Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency
|
Phase 2 | |
Completed |
NCT01419158 -
Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)
|
N/A | |
Recruiting |
NCT00500123 -
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
|
||
Completed |
NCT05727800 -
A Phase 1, First-in-human Study of VX-668
|
Phase 1 | |
Active, not recruiting |
NCT05643495 -
A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype
|
Phase 2 | |
Completed |
NCT02810327 -
Alpha-1 Carrier Genomics Study
|
||
Terminated |
NCT02363946 -
A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)
|
Phase 1 | |
Completed |
NCT03804021 -
Long-Term Follow-up Study of ADVM-043
|
||
Active, not recruiting |
NCT02014415 -
Alpha-1 Antitrypsin Deficiency Adult Liver Study
|
||
Terminated |
NCT01241942 -
Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability
|
N/A |